Moleculin Biotech Files 8-K with Financials
Ticker: MBRX · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1659617
Sentiment: neutral
Topics: financial-statements, exhibits
TL;DR
Moleculin Biotech dropped an 8-K with financial updates. Check it for the latest numbers.
AI Summary
On June 5, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial status and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides investors with updated financial information and exhibits, which are crucial for assessing the company's current financial health and operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate adverse events.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Moleculin Biotech, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 5, 2025, as stated under 'DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 5, 2025'.
What is Moleculin Biotech, Inc.'s principal executive office address?
Moleculin Biotech, Inc.'s principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the Commission File Number for Moleculin Biotech, Inc.?
The Commission File Number for Moleculin Biotech, Inc. is 001-37758.
What is the Standard Industrial Classification (SIC) code for Moleculin Biotech, Inc.?
The Standard Industrial Classification (SIC) code for Moleculin Biotech, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Moleculin Biotech, Inc. (MBRX).